Associated Papers
Suboptimal molecular response to tyrosine kinase inhibition associated with acquisition of a T240A ABL1 kinase domain mutation in a patient with chronic myeloid leukemia.
Langabeer SE et al.
Experimental Oncology, 2019
BCR-ABL V280G Mutation, Potential Role in Imatinib Resistance: First Case Report.
Azevedo AP et al.
Clinical Medicine Insights. Oncology, 2017
Select a paper to view details